Publications by authors named "D Dizon"
Purpose: To explore the potential relationship between social media (SoMe) and burnout or overall wellbeing within the field of oncology.
Design: A cross-sectional study of adult and pediatric oncology professionals conducted using an anonymous electronic survey. The survey was disseminated through the Children's Oncology Group (COG) and the SWOG Cancer Research Network (SWOG) member listservs.
In the United States, over 2 million individuals openly identify with a gender that differs from their sex assigned at birth. A cancer diagnosis is physically and psychologically taxing-and, in some, traumatic. However, for transgender and gender-diverse (TGD) people, many of whom have experienced discrimination in myriad health care settings, the challenges may be even greater.
View Article and Find Full Text PDFArticle Synopsis
- Electronic patient-reported outcomes (ePROs) can enhance cancer patient care, but integrating them into clinical systems poses significant challenges, requiring technical resources, clinician and patient commitment, and institutional support.* -
- The SIMPRO Research Consortium created and implemented eSyM, an ePRO-based symptom management program across six cancer centers, tracking implementation methods and barriers through established frameworks and tools like REDCap.* -
- Out of 226 documented implementation strategies, 64 unique strategies were identified, with universal strategies that were consistently effective focusing on clinical preparation, training, and patient/clinician engagement being seen as particularly impactful.*
Article Synopsis
- Imlunestrant is a next-generation oral selective estrogen receptor degrader being tested in the EMBER trial for patients with ER+ advanced breast cancer and endometrioid endometrial cancer (EEC).
- The trial involves a dose-escalation design to determine optimal doses and measure safety, pharmacokinetics, and anticancer effects, focusing specifically on patients who have already undergone certain previous treatments.
- Results showed manageable side effects and some evidence of antitumor activity, with better outcomes observed when imlunestrant was combined with abemaciclib compared to imlunestrant alone.